Phase I Clinical Study of in Vivo Distribution and Metabolic Kinetic Characterization of 89Zr-Oxine-RY_SW01 Cell Injection for the Treatment of Systemic Sclerosis
Latest Information Update: 16 Jul 2024
At a glance
- Drugs RY SW01 (Primary)
- Indications Systemic scleroderma
- Focus Therapeutic Use
- Sponsors Jiangsu Renocell Biotech Company
Most Recent Events
- 16 Jul 2024 New trial record